Cetera Investment Advisers Esperion Therapeutics, Inc. Transaction History
Cetera Investment Advisers
- $55.9 Billion
- Q2 2025
A detailed history of Cetera Investment Advisers transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Cetera Investment Advisers holds 19,037 shares of ESPR stock, worth $54,826. This represents 0.0% of its overall portfolio holdings.
Number of Shares
19,037
Previous 21,764
12.53%
Holding current value
$54,826
Previous $31,000
41.94%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding ESPR
# of Institutions
184Shares Held
108MCall Options Held
139KPut Options Held
604K-
Black Rock Inc. New York, NY14MShares$40.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.7MShares$33.7 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT10.3MShares$29.8 Million0.05% of portfolio
-
Two Seas Capital LP Rye, NY9.95MShares$28.7 Million0.18% of portfolio
-
Pender Fund Capital Management Ltd. Vancouver, A16.68MShares$19.2 Million4.26% of portfolio
About Esperion Therapeutics, Inc.
- Ticker ESPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 66,551,600
- Market Cap $192M
- Description
- Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...